Following the success of the 63rd U.S.-Japan Business Conference, we would like to follow up on our advocacy efforts on pharmaceutical, therapy, and med tech repricing issues. On November 5, we are convening an in-person meeting to discuss our advocacy strategy for the remainder of 2026.

On September 30, the Ministry of Health, Labour and Welfare (MHLW) proposed at the Central Social Insurance Medical Council (Chuikyo) to expand price cuts under the Cost-Effectiveness Assessment (CEA) system. The direction of these policies continues to create significant challenges for the healthcare sector. Given these ongoing developments, it is important that the perspectives and concerns of U.S. companies are clearly communicated to relevant stakeholders and policymakers.

To that end, we would appreciate the opportunity to meet with you and discuss priorities, advocacy objectives, and next steps.

Thursday, November 5, 2026
2:30 PM - 3:30 PM (UTC-04:00) Eastern Time (US & Canada)